Literature DB >> 29465264

Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.

Uri Rozovski1,2, David M Harris1, Ping Li1, Zhiming Liu1, Preetesh Jain1, Alessandra Ferrajoli1, Jan Burger1, Phillip Thompson1, Nitin Jain1, William Wierda1, Michael J Keating1, Zeev Estrov1.   

Abstract

Unlike normal B-cells, and similar to fat cells, chronic lymphocytic leukemia (CLL) cells aberrantly express lipoprotein lipase (LPL), which contributes to free fatty acids (FFAs) metabolism. Here we show that, in CLL cells, the B-cell receptor (BCR) inhibitor ibrutinib reduced LPL mRNA and protein levels and inhibited FFA metabolism in vitro. Likewise, in CLL cells from ibrutinib-treated patients, FFA metabolism was reduced and eventually stopped. Because ibrutinib disrupts CLL cells' ability to use FFAs for energy production, and because various BCR-dependent cellular functions rely on a continuous supply of chemical energy, ibrutinib interrupts several pathways imperative for cellular function in CLL cells.

Entities:  

Keywords:  CLL; ibrutinib; lipoprotein lipase; metabolism

Mesh：

Substances：

Year:  2018        PMID： 29465264      PMCID： PMC6135679          DOI： 10.1080/10428194.2018.1439167

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


  22 in total

1.  Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.

Authors:  Sarah E M Herman; Rashida Z Mustafa; Jennifer A Gyamfi; Stefania Pittaluga; Stella Chang; Betty Chang; Mohammed Farooqui; Adrian Wiestner
Journal:  Blood       Date:  2014-03-21       Impact factor: 22.113

2.  Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.

Authors:  Martin F M de Rooij; Annemieke Kuil; Arnon P Kater; Marie José Kersten; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

3.  High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia.

Authors:  D Heintel; D Kienle; M Shehata; A Kröber; E Kroemer; I Schwarzinger; D Mitteregger; T Le; A Gleiss; C Mannhalter; A Chott; J Schwarzmeier; C Fonatsch; A Gaiger; H Döhner; S Stilgenbauer; U Jäger
Journal:  Leukemia       Date:  2005-07       Impact factor: 11.528

4.  Lipoprotein lipase in chronic lymphocytic leukaemia - strong biomarker with lack of functional significance.

Authors:  Edit Porpaczy; Stefanie Tauber; Martin Bilban; Gerhard Kostner; Michaela Gruber; Sandra Eder; Daniel Heintel; Trang Le; Karin Fleiss; Cathrin Skrabs; Medhat Shehata; Ulrich Jäger; Katrina Vanura
Journal:  Leuk Res       Date:  2013-03-07       Impact factor: 3.156

5.  Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.

Authors:  Prithviraj Bose; Varsha V Gandhi; Michael J Keating
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-11       Impact factor: 4.481

6.  BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.

Authors:  S Cheng; J Ma; A Guo; P Lu; J P Leonard; M Coleman; M Liu; J J Buggy; R R Furman; Y L Wang
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528

7.  WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.

Authors:  Alessandra Ferrajoli; Stefan Faderl; Quin Van; Patricia Koch; David Harris; Zhiming Liu; Inbal Hazan-Halevy; Yongtao Wang; Hagop M Kantarjian; Waldemar Priebe; Zeev Estrov
Journal:  Cancer Res       Date:  2007-12-01       Impact factor: 12.701

8.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

9.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

10.  Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML.

Authors:  Lyubov Zaitseva; Megan Y Murray; Manar S Shafat; Matthew J Lawes; David J MacEwan; Kristian M Bowles; Stuart A Rushworth
Journal:  Oncotarget       Date:  2014-10-30
View more
  10 in total

1.  LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.

Authors:  Wei Liu; Jan A Burger; Jie Xu; Zhenya Tang; Gokce Toruner; Mahsa Khanlari; L Jeffrey Medeiros; Guilin Tang
Journal:  Ann Hematol       Date:  2020-08-24       Impact factor: 3.673

Review 2.  Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies.

Authors:  George Robinson; Ines Pineda-Torra; Coziana Ciurtin; Elizabeth C Jury
Journal:  J Clin Invest       Date:  2022-01-18       Impact factor: 14.808

Review 3.  The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.

Authors:  Haoran Wang; Wentao Zhang; Jingyi Yang; Keshu Zhou
Journal:  Hematol Oncol       Date:  2021-10-15       Impact factor: 4.850

4.  Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice.

Authors:  Hye Yeon Nam; Jin Han Nam; Gwangho Yoon; Ju-Young Lee; Youngpyo Nam; Hye-Jin Kang; Hyun-Ji Cho; Jeongyeon Kim; Hyang-Sook Hoe
Journal:  J Neuroinflammation       Date:  2018-09-19       Impact factor: 8.322

5.  Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes.

Authors:  Gabriela Galicia-Vázquez; Raquel Aloyz
Journal:  Front Oncol       Date:  2018-09-26       Impact factor: 6.244

6.  Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes.

Authors:  Bahram Sharif-Askari; Daniel Doyon; Miltiadis Paliouras; Raquel Aloyz
Journal:  Sci Rep       Date:  2019-07-30       Impact factor: 4.379

Review 7.  Single-Cell Metabolomics in Hematopoiesis and Hematological Malignancies.

Authors:  Fengli Zuo; Jing Yu; Xiujing He
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

Review 8.  Lipotoxicity as a Barrier for T Cell-Based Therapies.

Authors:  Romy Böttcher-Loschinski; Judit Rial Saborido; Martin Böttcher; Sascha Kahlfuss; Dimitrios Mougiakakos
Journal:  Biomolecules       Date:  2022-08-25

9.  Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia.

Authors:  Xiaoya Yun; Xiang Sun; Xinting Hu; Huimin Zhang; Zixun Yin; Xin Zhang; Ming Liu; Ya Zhang; Xin Wang
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

10.  Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma.

Authors:  Zhuojun Liu; Jia Liu; Tianming Zhang; Lin Li; Shuo Zhang; Hao Jia; Yuanshi Xia; Mingxia Shi; Jing Zhang; Shuhua Yue; Xiaofang Chen; Jian Yu
Journal:  BMC Cancer       Date:  2021-06-26       Impact factor: 4.430
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.